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Achieving bacterial eradication using pharmacokineticl 
pharmacodynamic principles 
Ron Dagan(l) 
Evidence from studies in otitis media indicates that antimicrobials and dosing regimens that have equivalent 
bacteriologic efficacy against susceptible pathogens can have significantly different bacteriologic success rates against 
resistant strains of the same species. Unlike macrolide and fluoroquinolone resistance, penicillin resistance can be 
overcome in Streptococcus pneumoniae by increasing the dose, and hence increasing the time for which the serum 
concentrations are above the MIC. The new clinical formulation of extra-strength amoxicillin-clavulanate provides 
90 mg/kg per day amoxicillin plus 6.4 mg/kg per day clavulanate (14:l) divided every 12 h, compared with 
45/6.4 mg/kg per day b.i.d. with conventional dosing. The pharmacokinetic/pharmacodynamic (PK/PD) profiles of 
extra-strength amoxicillin-clavulanate predict that the new formulation will be more effective than the conventional 
formulation against S. pneumoniae with elevated amoxicillin MICs and against Haemophilus influenzae. In an open- 
label, non-comparative study in children with acute otitis media, the extra-strength formulation had high bacteriologic 
success rates against the major respiratory pathogens, including penicillin-resistant S. pneumoniae. The development 
of new antimicrobial agents and formulations should be aimed at meeting PKiPD parameters predictive of bacterial 
eradication of both susceptible and resistant strains. 
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INTRODUCTION 
Bacterial eradication is necessary to maximize clinical 
cure and minimize resistance development and spread 
(see J. Garau, this issue). It is now widely recognized that 
the interaction of pharmacokinetic (PK) and pharma- 
codynamic (PD) parameters determines the in vivo 
bacteriologic efficacy of antimicrobial agents.r For 
B-lactams, macrolides, clindamycin, and cotrimoxazole, 
bactericidal activity is dependent on the length of time 
for which drug concentrations in the serum and/or at the 
site of infection are above the MIC for an organism 
(T >MIC). 2,3 For aminoglycosides, fluoroquinolones, 
and azithromycin, the ratio of the area under the concen- 
tration-time curve (AUC) to the MIC for an organism 
best predicts bactericidal activity.2 These predictions can 
be used to develop breakpoints predictive of bacterial 
eradication, which are dependent on the PK profile, 
dosing regimen, and MIC of the antimicrobial. The 
article by M. R. Jacobs (this issue) provides a detailed 
outline of the basis of PKiPD antimicrobial assessment 
and the derivation of PK/PD breakpoints that can 
be used to predict bacterial eradication. Despite these 
advances, studies testing the clinical relevance of PK/PD 
profiles in human respiratory tract infections (RTIs) 
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have been lacking, primarily due to the difficulty in 
obtaining reliable microbiological samp1es.l 
Acute otitis media is a common infection, parti- 
cularly in children, with approximately 70% of cases 
having an identified causative bacterial pathogen.4 As 
with RTIs, the most common pathogens implicated are 
Streptococcus pneumoniae, Haemophilus infiuenzae, and 
Moraxella catavrhalis.5 Samples of middle ear fluid can 
be obtained by tympanocentesis before, during and after 
antimicrobial treatment, and cultured to identify the 
organisms present. Thus, the bacteriologic effect of anti- 
microbial therapy can be assessed directly, and can then 
be correlated with both clinical observations and pre- 
dictions from PK/PD calculations. Acute otitis media 
therefore represents a good model in which to’study the 
application of PK/PD principles to the antimicrobial 
therapy of RT1s.r 
Another advantage of acute otitis media as a model 
is the availability of data relating to rates of spontaneous 
resolution. In a classic study performed 30 years ago, 
Howie and Ploussard aspirated middle ear fluid from 
280 children with acute otitis media before and after 
starting treatment.6 In 116 children receiving placebo, 
middle ear culture before treatment was positive for 
S. pneumoniae in 42% and H. influenzae in 21% of 
patients. After 2-7 days of placebo therapy, S. pneu- 
moniae persisted in 84% and H. influenzae in 52% of 
cases in which they were identified. In other words, 
placebo (or no antimicrobial treatment) ‘eradicates’ 
S. pneumonide in about 15% of patients and H. infruenzae 
in about 50% of patients within a few days, and this 
represents the baseline comparator for the efficacy of 
antimicrobials within 3-5 days.6 
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This paper examines the evidence supporting the 
use of PK/PD breakpoints clinically in otitis media, and 
how PK/PD principles can be applied to drug develop- 
ment. 
PREDICTING BACTERIOLOGIC FAILURE 
IN OTITIS MEDIA 
Available data for bacteriologic failures in double- 
tympanocentesis studies of otitis media are summarized 
in Table 1.6-16 It is obvious from these data that some 
commonly used antimicrobials are failing to provide 
adequate therapy in this indication. But are these failure 
rates consistent with what would have been predicted 
using PK/PD parameters? 
Haemophilus injiuenzae 
The first thing that is obvious from Table 1 is that, of 
the drugs presented in the table, only ceftriaxone and 
cefixime achieve complete eradication of H. injluenzae. 
Both of these agents are highly active against Gram- 
negative pathogens. i7 In the two studies cited, however, 
the MICs of ceftriaxone against H. influenzae ranged 
from 0.006 mg/L to 0.5 mg/L.14215 Gudnason et al found 
that a single intramuscular dose of 50 mg/kg ceftriaxone 
gave a peak concentration in middle ear fluid of 35 mg/L 
at about 24 h, and concentrations were maintained 
above the MI&, for the three major respiratory 
pathogens, including H., influenzae, for approximately 
120 h.18 As ceftriaxone is highly bound to protein, the 
free concentrations are presumed to be much lower, but 
still above the MIC of H. injkerzzae for a considerable 
amount of time. Given that a time above MIC of about 
40-50% of the dosing interval is predictive of bacterio- 
logic eradication for cephalosporins, the high efficacy of 
ceftriaxone against H. influenzae in these studies is 
expected, based on PK/PD predictions.2 Cefixime is a 
P-lactamase-stable oral cephalosporin with a PK/PD 
breakpoint of 1 mg/L (see M. R. Jacobs, this issue, 
for PK/PD breakpoints). The MICs for cefixime against 
H. influenzae in the study by Johnson et al were not pro- 
vided for bacterial pathogens isolated post-treatmentI 
It is not, therefore, possible to compare the cefixime 
MICs with the PK/PD breakpoint for this agent. 
Several agents in Table 1 have failure rates of over 
25 % against H. influenzae (azithromycin, amoxicillin 
(for P-lactamase-producing organisms), and cefaclor). 
In particular, the failure rates with azithromycin for all 
H. in@enzae strains, with amoxicillin for p-lactamase- 
producing H. influenzae strains, and with cotrimoxazole 
for cotrimoxazole-resistant H. injhenzae strains, are in 
the range observed with placebo (Table 1).7,8,12,13,16 The 
PK/PD breakpoint for azithromycin against H. influenzae 
is 0.12 mg/L, and in the two studies of azithromycin, 
MICs for this antimicrobial against H. influenzae were 
between 0.25 mg/L and 54 mg/L,* and 0.5-S mg/L.7 The 
observed high bacteriologic failure rate of azithromycin 
is, therefore, entirely consistent with PK/PD predictions. 
These data have important implications for clinical 
practice when applied to reported azithromycin MIC 
distributions. For example, data from the Alexander 
Project, a prospective worldwide surveillance study, 
show that 99% of azithromycin MICs against 2240 
H. influenzae strains isolated, in 2001 were above the 
0.12 mg/L breakpoint.17 Thus, azithromycin, as well 
as other macrolide agents, would be predicted to be 
almost universally bacteriologically ineffective against 
H. injluenzae.17 
Cefaclor also has very poor in vivo bacteriologic 
efficacy against H. influenzae (Table 1).8,12,13 Although 
cefaclor is a non+-lactamase-stable cephalosporin, 
Table 1. Bacteriologic failure rates in otitis media for commonly prescribed antimicrobials compared with placebo, after 3-5 days of 
therapy6-I6 
Bacteriologic failure rate, 
% (n/N) on day4-6 
Antimicrobial Dose 5. pneumoniae 
Placeboa 84 (48157) 
Azithromycin 
Amoxicillin 
Amoxicillin-clavulanate 
Cefaclor 
Ceftriaxone 
(intramuscular dosing) 
Cefuroxime axetil 
Cefixime 
Cotrimoxazole 
10 mg/kg day 1, 5 mg/kg/day o.d. 21 (7/33) 
10 mg/kg/day o.d. 33 (6/18) 
80 mglkgiday t.i.d. 11 (2/18) 
50 mg/kg/day t.i.d. 17 (4/24) 
40 mglkglday 7 (l/15) 
4516.4 mglkglday b.i.d. 7 (2/29) 
40 mg/kg/day t.i.d. 48 (16/33) 
40 mg/kg/day t.i.d. 22 (8/37) 
40 mg/kg/day b.i.d. 20 (4/20) 
50 mglkglday o.d. for 1 day 43 (13/30) 
50 mglkglday o.d. for 3 days 3 (l/35) 
50 mglkglday o.d. for 3 days 13 (6/47) 
30 mglkglday b.i.d. 15 (6/41) 
8 mg/kg/day o.d. or b.i.d 25 (4/16) 
8140 mglkglday b.i.d. 46 (11/24) 
8140 mglkglday b.i.d. 0 (O/l 9) 
H. influenzae 
52 (13/25) 
61 (28/46) 
63 (22135) 
25 (6/24) 
27 (g/33) 
38 (5/13) 
23 (g/39) 
62 (18/29) 
39 (22157) 
44 (8118) 
0 iol27j 
0 (O/38) 
0 (O/54) 
15 (7/46) 
0 (O/l 0) 
18 (7/40) 
7 (l/14) 
Reference no. 
6 
7 
8 
9 
10 
11 
7 
8 
12 
13 
14 
14 
15 
12 
11 
16 
13 
a Day 2-7. 
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it also has low inherent efficacy against p-lactamase- 
negative strains. Based on a PK/PD target of a T >MIC 
of 40%, the PK/PD breakpoint for cefaclor is 0.5 mg/L. 
Information on cefaclor MICs for the infecting pathogens 
are available from two studies.*J2 Combined data from 
these studies show that bacteriologic failure was similar 
against strains with cefaclor MICs >l mg/L (41% (25161)) 
to that seen against strains with MICs ~1 mg/L (50% 
(12/22)), suggesting that the breakpoint should be 
<1 mg/L.8J2 In the 2001 Alexander Project, 98% of 
cefaclor MICs against 1893 @-lactamase-negative 
H. influenzae isolates were >0.5 mg/L, and 98% exceeded 
this concentration against 347 p-lactamase-positive 
strains.17 As very few strains have cefaclor MICs 
~0.5 mg/L, it is difficult to confirm the PK/PD 
breakpoint exactly using H. ir@enzae. What is certain, 
however, is that cefaclor provides suboptimal bacterial 
efficacy against both p-lactamase-positive and -negative 
H. influenzae strains, with results similar to those obtained 
with placebo.6 
Amoxicillin is not stable to p-lactamase, and so its 
bacteriologic efficacy against H. inpuenzae will be deter- 
mined by the presence of p-lactamase-producing strains. 
In a study in which the amoxicillin failure rate overall 
against H. influenzae was 27%, the failure rate against 
P-lactamase-positive strains was 60% (3/5), compared 
with 21% (6/28) against P-lactamase-negative strains.lO 
In contrast, for amoxicillin combined with the p-lactamase 
inhibitor clavulanate, P-lactamase-positive H. injluenzae 
was successfully eradicated from Xi9 patients.7 Cefuroxime 
axetil, a P-lactamase-stable cephalosporin, has a relatively 
low rate of bacteriologic failure against H. injkenzae 
(13%). The PK/PD breakpoint of cefuroxime axetil is 
1 mg/L, and the bacteriologic failure rate corres- 
ponds well with this, with 100% (l/l) failures against 
H. influenzae strains with cefuroxime MICs >2 mg/L, 
20% (11.5) failures for MICs 1.5-2 mg/L, and 11% (4/38) 
failures for MICs ~1 mg/L.12 
The impact of cotrimoxazole resistance in 
H. influenzae was indicated in one study in which 100% 
(28128) of H. injluenzae strains with cotrimoxazole MICs 
~0.5 mg/L were eradicated, compared with 50% (6/12) 
for MICs 20.5 mg/L.16 No PK/PD breakpoint has been 
determined for cotrimoxazole, but the effect of resist- 
ance on bacteriologic efficacy can be clearly seen.16 
Streptococcus pneumoniae 
Resistance in S. pneumoniae exists for all the commonly 
used classes of antimicrobial, and will have a major 
influence on bacteriologic efficacy. Agents with more 
favorable PK/PD profiles will be able to retain activity 
against pathogens with elevated MICs, whereas the 
efficacy of those with marginal PK/PD profiles will be 
undermined. Cotrimoxazole provides a unequivocal 
example of the negative impact of bacterial resistance in 
S. pneumoniae on bacteriologic efficacy.16 Among 67 
organisms isolated from 54 children with otitis media, all 
S. pneumoniae strains with a cotrimoxazole MIC of 
~0.5 mg/L were eradicated.16 In contrast, bacteriologic 
failure was 73% (11/15) for S. pneumoniae strains with 
cotrimoxazole MICs 20.5 mg/L, i.e. similar to that of 
placebo (84% bacteriologic failure).6 
The Gram-positive activity of the cephalosporins 
varies greatly between the different agents, and in- 
creasing bacterial resistance will impact upon the 
weaker members of the class first. For example, in the 
2001 Alexander Project, the MICSOS of cefaclor were 
1 mg/L against penicillin-susceptible S. pneumoniae 
(n=1654), 4 mg/L against intermediate strains (n=378), 
and >64 mg/L against resistant strains (n=451).17 In 
comparison, the MICsos for cefuroxime in the same 
study were 0.03 mg/L, 0.5 mg/L, and 8 mg/L, respec- 
tively.17 Given that the PK/PD breakpoint of cefaclor is 
0.5 mg/L, it would be expected to be active against some 
penicillin-susceptible strains, a minority of the penicillin- 
intermediate strains, and none of the penicillin-resistant 
strains. With a PK/PD breakpoint of 1 mglL, cefuroxime 
would be expected to be effective against the majority 
of penicillin-susceptible strains, many penicillin-inter- 
mediate strains, and none of the penicillin-resistant 
strains. A comparative clinical study of cefaclor and 
cefuroxime axetil illustrates this.12J9 At day 4-5, 
bacteriologic persistence of penicillin-susceptible 
S. pneumoniae strains was observed in similar percentages 
of children treated with cefaclor (4% (P/25)) and with 
cefuroxime axetil (9% (2/22)) (Figure 1).6J9 However, 
against penicillin-intermediate strains, while bacterio- 
logic failure occurred in 58% (702) of children after 
cefaclor treatment, failure occurred in only 21% (4/19) 
of children treated with cefuroxime axetil.19 As 
predicted from the PK/PD breakpoints for these two 
cephalosporins, therefore, cefaclor and cefuroxime axetil 
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Figure 1. Bacteriologic failure rates in children with acute 
otitis media treated with oral cefuroxime axetil or cefaclor 
against penicillin-susceptible (Pen-S) and penicillin-intermediate 
(Pen-l) 5. pneumoniae, compared with placebo failure rates. 
Data from Dagan et all2 and Howie and Ploussard.6 
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have similar bacteriologic efficacy against penicillin- 
susceptible S. pneumoniae strains, whereas against 
penicillin-intermediate strains, cefuroxime retains good 
activity and cefaclor is little better than placebo.6J9 
Although no PKiPD breakpoint has been calculated 
for intramuscular ceftriaxone, a study comparing the 
effect of a l-day versus a 3-day dosing regimen indicates 
the importance of changes in PK/PD characteristics for 
bacteriologic response. l4 Children with nonresponsive 
acute otitis media were given a 50 mg/kg per day 
dose of intramuscular ceftriaxone for either 1 or 3 
days.14 Bacterial eradication of penicillin-susceptible 
S.pneumoniae strains was achieved by day 4-5 with both 
regimens. However, bacteriologic failure with the l-day 
regimen was 48% (13/27) for penicillin-non-susceptible 
strains, compared with 3% (l/34) for the 3-day regi- 
men.14 
Studies in otitis media have also demonstrated 
the impact of macrolide resistance on bacteriologic 
outcomes with macrolide therapy.7,s For azithromycin, 
the PK/PD breakpoint is 0.12 mg/L. Two studies 
are relevant in terms of determining whether or not 
these predictions are supported by bacterial eradication 
rates with azithromycin treatment in children with acute 
otitis media,7,s and the results are summarized in Figure 
2. 6-8 Combined data from these two studies indicate that 
bacteriologic failure against strains with azithromycin 
MICs so.25 mg/L was 5% (2/37), compared with 79% 
(11/14) for MICs >2 mg/L, i.e. no better than placebo. 
In the 2001 Alexander Project, the MICSO and MIC90 of 
azithromycin were both 0.12 mg/L against 1732 erythro- 
mycin-susceptible S. pneumoniae strains, and so most of 
these strains would be eradicated with erythromycin 
therapy. l7 However, against 749 erythromycin-resistant 
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Figure 2. The effect of macrolide resistance in 5. pneumoniae 
on bacteriologic failure rates with 3 or 5 days of azithromycin 
treatment in children with acute otitis media, compared with 
placebo. Data from Dagan et a17f8 and Howie and Ploussard.‘j 
strains, the azithromycin MICSO and MI& were both 
>32 mg/L, and only one strain had an azithromycin 
MIC of <l mg/L.i7 Thus, based on PK/PD parameters, 
azithromycin would be predicted to be ineffective 
against all erythromycin-resistant strains. 
PIUPD-DIRECTED THERAPY 
Using PK/PD predictions, a 3-day course of intra- 
muscular ceftriaxone is the most effective therapy 
currently available for the treatment of otitis media, and 
this is supported by clinical data (Table 1). However, 
administration of the doses requires clinic visits on three 
consecutive days, which can be inconvenient for many 
parents. As far as oral therapy is concerned, amoxicillin- 
clavulanate currently provides the greatest coverage 
of the major pathogens, followed by cefuroxime axetil. 
Cefuroxime axetil30 mg/kg per day will provide coverage 
of penicillin-susceptible and -intermediate pneumococci, 
and is stable against p-lactamase-producing H. in@- 
enzae and M. cataruhalis. Amoxicillin-clavulanate is 
also effective against p-lactamase-producing strains. 
In addition, with a PK/PD breakpoint of 2 mg/L for a 
40-50 mg/kg per day dose, amoxicillin +- clavulanate 
has high predicted activity against S. pneumoniae- 
amoxicillin MI&s in the 2001 Alexander Project were 
0.03 mg/L for penicillin-susceptible, 0.25 mg/L for peni- 
cillin-intermediate and 2 mg/L for penicillin-resistant 
S. pneumoniae. i7 For the penicillin-susceptible and 
-intermediate strains, none of the amoxicillin MICs were 
>2 mg/L, so all of these strains and about 80% of 
penicillin-resistant strains will be covered by amoxi- 
cillin-clavulanate.17 However, particularly in areas of 
high resistance prevalences, there remains a need for an 
oral agent with bacteriologic efficacy comparable with, 
or better than, that of intramuscular ceftriaxone. 
With the penicillins, it is possible to increase the 
time above MIC (T >MIC) by increasing the dose. If 
higher concentrations can be maintained for a longer 
period, it will be possible to provide coverage for higher 
MICs. The standard regimen of amoxicillin-clavulanate 
of 4516.4 mg/kg per day b.i.d. provides amoxicillin 
concentrations in excess of 2 mg/L for more than 40% of 
the dosing interval, i.e. the T >MIC predictive of bacterial 
eradication.20,21 Doubling the dose of amoxicillin to 
90 mg/kg per day b.i.d. improves the PK of the 
formulation to provide amoxicillin concentrations that 
exceed an MIC of 4 mg/L for 41% of the dosing 
interval.*l Thus, the PK/PD breakpoint is doubled, and 
a greater proportion of strains can be covered. Based on 
2001 Alexander Project MIC distributions, the bacterio- 
logic efficacy of oral amoxicillin-clavulanate 90 mg/kg 
per day b.i.d. should be comparable to that of intra- 
muscular ceftriaxone (Table 2).i7 
A recent international study has examined the 
bacteriologic efficacy of extra-strength amoxicillin- 
clavulanate in otitis media in children. The study 
included patients with risk factors for penicillin-resistant 
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Table 2. Percentages of penicillin-susceptible (Pen-S), penicillin-intermediate (Pen-l) and penicillin-resistant (Pen-R) 5. pneumoniae 
and 6-lactamase-positive and -negative H. influenzae strains isolated in the 2001 Alexander Project susceptible to conventional 
(45/6.4 mglkglday) and extra-strength (90/6.4 mglkglday) formulations of amoxicillin-clavulanate (AMWCA), compared with 
ceftriaxone and amoxicillin17 
Susceptibility (%) 
Antimicrobial 
PKIPD 
breakpoint 
fmglL) 
Streptococcus pneumoniae Haemophilus influenzae 
Pen-S Pen-l Pen-R P-Lactamase+ P-Lactamase- 
(n=1654) (n=378) (n=451) (n=347) (n= 1893) 
Amoxicillin 2 100 100 78.3 0.6 97.7 
AMXKA 2 100 99.7 78.9 96.3 97.8 
Extra-strength AMX/CA 4 100 100 89.6 100 99.4 
Ceftriaxone a 100 99.7 80.7 100 99.9 
aNCCLS breakpoints used: ~1 mg/L for 5. pneumoniae (non-meningitis), ~2 mg/L for H. influenzae. 
S. pneumoniae infection and recurrent acute otitis media. 
Tympanocentesis was conducted before and after 4-6 
days of treatment. 22 Bacteriologic failure was observed 
in 4% (8080) of children overall, with failure rates 
of 2% (3/125) for S. pneumoniae and 6% (5/83) for 
H. influenzae.22 When these results are compared with 
bacterial eradication rates obtained with the standard 
amoxicillin-clavulanate dose,7 it can be seen that 
persistence of H. injhenzae is significantly reduced with 
the extra-strength formulation (p=O.Ol, Figure 3).7,22 
This brings the eradication rate for extra-strength 
amoxicillin-clavulanate more into line with that of 
ceftriaxone (94% versus lOO%, respectively).14J5,22 The 
persistence of S. pneumoniae was also reduced with the 
extra-strength formulation, though not significantly.7,22 
The bacteriologic failure rate was 0% (88/88) with 
amoxicillin-clavulanate 90/6.4 mg/kg per day b.i.d. against 
penicillin-susceptible and -intermediate S. pneumoniae 
and 9% (31/34) against penicillin-resistant strains 
(penicillin MICs 82 mg/L).22 In comparison, studies of 
‘;; 80 
; 70 
$ 60 
p=O.Ol 
S. pneumoniae H. influenzae 
1 n 4516.4 mglkglday q 9016.4 mglkglday 1 
Figure 3. Comparison of bacteriologic failure rates with 
conventional amoxicillin-clavulanate (45 mglkg per day of 
amoxicillin) and extra-strength amoxicillin-clavulanate 
(90 mg/kg per day of amoxicillin). Data from Dagan et al.8J2 
a 3-day course of intramuscular ceftriaxone report 
bacteriologic failure rates of 12% (4/34) and 3% (l/34) 
against penicillin-intermediate strains-no data are 
available for penicillin-resistant strains.14J5 
The successful development of the extra-strength 
amoxicillin-clavulanate 90/6.4 mg/kg per day b.i.d. 
formulation indicates that, by using PK/PD principles to 
guide changes in antimicrobial dosing, it is possible to 
achieve greater eradication rates of the main pathogens 
of acute otitis media, and hence improve clinical success. 
CONCLUSIONS 
Double-tympanocentesis studies in otitis media provide 
strong evidence supporting the clinical relevance of 
PK/PD predictions of bacteriologic efficacy. Considera- 
tion of the data outlined in this paper indicate that only 
limited choices now exist for the treatment of children 
with acute otitis media. Some agents have suboptimal 
PK/PD characteristics even in the absence of resistance, 
such as macrolides and cefaclor against H. influenzae. 
Increased prevalences of resistance will initially under- 
mine the bacteriologic efficacy of antimicrobials with 
marginal PK/PD profiles, e.g. macrolide resistance in 
S. pneumoniae. However, all currently available therapy 
will be compromised if bacteriologic susceptibility 
decreases sufficiently. It is, therefore, important that 
we are not complacent and continue to develop new 
antimicrobials and formulations with improved PK/PD 
profiles. The development of the extra-strength formu- 
lation of amoxicillin-clavulanate (90/6.4 mg/kg per day 
b.i.d.) has shown that PK/PD principles can be directly 
applied to the optimization of antimicrobial therapy. The 
choice of current antimicrobial therapy and the develop- 
ment of new antimicrobial agents and formulations 
should aim to meet PK/PD parameters predictive of 
bacterial eradication of both susceptible and resistant 
strains. 
REFERENCES 
1. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to 
support the rationale that bacterial eradication in respira- 
S26 International Journal of Infectious Diseases / Volume 7, Supplement 1,2003 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
tory tract infection provides guidance for antimicrobial 
therapy. J Antimicrob Chemother 2000; 47:129-140. 
Craig WA. Pharmacokineticipharmacodynamic parameters: 
rationale for antibacterial dosing of mice and men. Clin 
Infect Dis 1998; 26:1-12. 
Craig WA, Andes D. Pharmacokinetics and pharmaco- 
dynamics of antibiotics in otitis media. Pediatr Infect Dis 
J 1996; 15255-259. 
McCracken GHJ. Prescribing antimicrobial agents for treat- 
ment of acute otitis media. Pediatr Infect Dis J 1999; 18: 
1141-1146. 
Dowel1 SF, Butler JC, Giebink GS, et al. Acute otitis media: 
management and surveillance in an era of pneumococcal 
resistance-a report from the Drug-Resistant Streptococcus 
pneumoniae Therapeutic Working Group. Pediatr Infect 
Dis J 1999; 18~1-9. 
Howie VM, Ploussard JH. Efficacy of fixed combination 
antibiotics versus separate components in otitis media. 
Effectiveness of erythromycin estolate, triple sulfonamide, 
ampicillin, erythromycin estolate-triple sulfonamide, and 
placebo in 280 patients with acute otitis media under two 
and one-half years of age. Clin Pediatr 1972; 11:205-214. 
Dagan R, Johnson CE, McLinn S, et al. Bacteriologic and 
clinical efficacy of amoxicillin/clavulanate vs. azithromycin 
in acute otitis media. Pediatr Infect Dis J 2000; 19:95-104. 
Dagan R, Leibovitz E, Fliss DM, et al. Bacteriologic 
efficacies of oral azithromycin and oral cefaclor in treat- 
ment of acute otitis media in infants and young children. 
Antimicrob Agents Chemother 2000; 44:43-50. 
Leibovitz E, Piglansky L, Raiz S, et al. The bacteriological 
and clinical efficacy of extra-strength amoxicillin (HD- 
AMOX, 80 mgikgiday tid) as first-line therapy for acute 
otitis media in children [Abstract 1061. In: Program and 
abstracts of the 40th Interscience Conference on Anti- 
microbial Agents and Chemotherapy, Toronto, Canada. 
Washington, DC: American Society for Microbiology, 
2000:491. 
Dagan R, Piglansky L, Yagupsky P Fliss DM, Leiberman 
A, Leibovitz E. Bacteriologic response in acute otitis 
media (AOM): comparison between azithromycin (AZ), 
cefaclor (CEC) and amoxicillin (AMOX) [Abstract 
K-1031. In: Program and abstracts of the 37th Interscience 
Conference on Antimicrobial Agents and Chemotherapy, 
Toronto, Canada. Washington, DC: American Society for 
Microbiology, 1997:346. 
11. Johnson CE, Carlin SA, Super DM, et al. Cefixime com- 
pared with amoxicillin for treatment of acute otitis media. 
J Pediatr 1991; 119:117-122. 
12. Dagan R, Abramson 0, Leibovitz E, et al. Bacteriological 
response to oral cephalosporins: are established suscepti- 
bility breakpoints appropriate in the case of otitis media? 
J Infect Dis 1997; 176:1253-1259. 
13. Marchant CD, Shurin PA,Turcyzk VA, et a1.A randomized 
controlled trial of cefaclor compared with trimethoprim- 
sulfamethoxazole for treatment of acute otitis media. 
J Pediatr 1984; 105:633-638. 
14. 
1.5 
16 
17. 
18. 
19. 
Leibovitz E, Piglansky L, Raiz S, Press J, Leiberman A, 
Dagan R. Bacteriologic and clinical efficacy of one day 
vs. three day intramuscular ceftriaxone for treatment of 
nonresponsive acute otitis media in children. Pediatr Infect 
Dis J 2000; 19:1040-1045. 
Leibovitz E, Piglansky L, Raiz S, et al. Bacteriologic 
efficacy of a three-day intramuscular ceftriaxone regimen 
in nonresponsive acute otitis media. Pediatr Infect Dis J 
1998; 17:1126-1131. 
Leiberman A, Leibovitz E, Piglansky L, et al. Bacteriologic 
and clinical efficacy of trimethoprim-sulfamethoxazole for 
treatment of acute otitis media. Pediatr Infect Dis J 2001; 
20:260-264. 
Alexander Project, 2001. Data on file, GlaxoSmithKline. 
Gudnason T, Gudbrandsson F, Barsanti F, Kristinsson 
KG. Penetration of ceftriaxone in the middle ear fluid of 
children. Pediatr Infect Dis J 1998; 17:258-260. 
Dagan R, Abramson 0, Leibovitz E, et al. Impaired 
bacteriologic response to oral cephalosporins in acute otitis 
media caused by pneumococci with intermediate resistance 
to penicillin. Pediatr Infect Dis J 1996; 15:980-985. 
20. Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Pankuch 
GA, Appelbaum PC. Susceptibilities of Streptococcus 
pneumoniae and Haemophilus influenzae to 10 oral 
antimicrobial agents based on pharmacodynamic para- 
meters: 1997 US surveillance study. Antimicrob Agents 
Chemother 1999; 43:1901-1908. 
21. Data on file, GlaxoSmithKline. 
22. Dagan R, Hoberman A, Johnson C, et al. Bacteriologic 
and clinical efficacy of high dose amoxicilliniclavulanate in 
children with acute otitis media. Pediatr Infect Dis J 2001; 
20:829-837. 
